Clinical benefit emerges precisely when DynamX unlocks at six months—trial data shows 48% risk reduction through two years in acute coronary syndrome patients.

Trial data shows how targeted anticoagulant delivery during peak thrombotic vulnerability translates to zero early complications versus 5% in controls—preventing heart attacks when ACS patients face greatest risk.

Engineering discovered your heart's natural calm window during each beat makes stent decisions possible without the drug that causes chest pain in most patients.